CZ20033222A3 - Použití alkanoyl L-karnitinu k přípravě léčiva k léčbě anhedonie - Google Patents
Použití alkanoyl L-karnitinu k přípravě léčiva k léčbě anhedonie Download PDFInfo
- Publication number
- CZ20033222A3 CZ20033222A3 CZ20033222A CZ20033222A CZ20033222A3 CZ 20033222 A3 CZ20033222 A3 CZ 20033222A3 CZ 20033222 A CZ20033222 A CZ 20033222A CZ 20033222 A CZ20033222 A CZ 20033222A CZ 20033222 A3 CZ20033222 A3 CZ 20033222A3
- Authority
- CZ
- Czechia
- Prior art keywords
- stress
- carnitine
- acetyl
- rats
- vab
- Prior art date
Links
- 208000007415 Anhedonia Diseases 0.000 title claims abstract description 13
- -1 alkanoyl L-carnitine Chemical compound 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical group CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 57
- 239000002253 acid Substances 0.000 claims description 19
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 59
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 56
- 230000002459 sustained effect Effects 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 33
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 32
- 229960004801 imipramine Drugs 0.000 description 32
- 229960003638 dopamine Drugs 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 235000009499 Vanilla fragrans Nutrition 0.000 description 21
- 244000263375 Vanilla tahitensis Species 0.000 description 21
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 15
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 15
- 229960002464 fluoxetine Drugs 0.000 description 15
- 239000008188 pellet Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000036327 taste response Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 229960003920 cocaine Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000013101 initial test Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 210000001009 nucleus accumben Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical group CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 1
- LRCNOZRCYBNMEP-SECBINFHSA-N O-isobutyryl-L-carnitine Chemical compound CC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LRCNOZRCYBNMEP-SECBINFHSA-N 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical group CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical group CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical group CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000292A ITRM20010292A1 (it) | 2001-05-29 | 2001-05-29 | Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia. |
| IT2001RM000319A ITRM20010319A1 (it) | 2001-06-08 | 2001-06-08 | Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20033222A3 true CZ20033222A3 (cs) | 2004-06-16 |
Family
ID=26332845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20033222A CZ20033222A3 (cs) | 2001-05-29 | 2002-05-24 | Použití alkanoyl L-karnitinu k přípravě léčiva k léčbě anhedonie |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040171685A1 (https=) |
| EP (1) | EP1399143B1 (https=) |
| JP (1) | JP2004532867A (https=) |
| KR (1) | KR20040003031A (https=) |
| AT (1) | ATE345124T1 (https=) |
| CA (1) | CA2448246A1 (https=) |
| CZ (1) | CZ20033222A3 (https=) |
| DE (1) | DE60216090T2 (https=) |
| DK (1) | DK1399143T3 (https=) |
| ES (1) | ES2275881T3 (https=) |
| HU (1) | HUP0400007A2 (https=) |
| MX (1) | MXPA03010920A (https=) |
| PL (1) | PL367628A1 (https=) |
| PT (1) | PT1399143E (https=) |
| SK (1) | SK15862003A3 (https=) |
| WO (1) | WO2002096411A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20020620A1 (it) * | 2002-12-13 | 2004-06-14 | Sigma Tau Ind Farmaceuti | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
| CA3238205A1 (en) | 2021-11-12 | 2023-05-19 | Rajaram Samant | A synergistic composition for activating intracellular secondary messenger(camp) pathway |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| IT1291930B1 (it) * | 1997-06-18 | 1999-01-21 | Sigma Tau Ind Farmaceuti | Composizione riequilibratrice delle turbe dell'umore in individui sani |
-
2002
- 2002-05-24 PL PL02367628A patent/PL367628A1/xx unknown
- 2002-05-24 DE DE60216090T patent/DE60216090T2/de not_active Expired - Fee Related
- 2002-05-24 CA CA002448246A patent/CA2448246A1/en not_active Abandoned
- 2002-05-24 WO PCT/IT2002/000339 patent/WO2002096411A1/en not_active Ceased
- 2002-05-24 SK SK1586-2003A patent/SK15862003A3/sk unknown
- 2002-05-24 EP EP02741156A patent/EP1399143B1/en not_active Expired - Lifetime
- 2002-05-24 HU HU0400007A patent/HUP0400007A2/hu unknown
- 2002-05-24 PT PT02741156T patent/PT1399143E/pt unknown
- 2002-05-24 AT AT02741156T patent/ATE345124T1/de not_active IP Right Cessation
- 2002-05-24 ES ES02741156T patent/ES2275881T3/es not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010920A patent/MXPA03010920A/es active IP Right Grant
- 2002-05-24 US US10/478,998 patent/US20040171685A1/en not_active Abandoned
- 2002-05-24 CZ CZ20033222A patent/CZ20033222A3/cs unknown
- 2002-05-24 DK DK02741156T patent/DK1399143T3/da active
- 2002-05-24 JP JP2002592921A patent/JP2004532867A/ja active Pending
- 2002-05-24 KR KR10-2003-7015576A patent/KR20040003031A/ko not_active Ceased
-
2005
- 2005-12-20 US US11/311,406 patent/US20060148896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE345124T1 (de) | 2006-12-15 |
| ES2275881T3 (es) | 2007-06-16 |
| CA2448246A1 (en) | 2002-12-05 |
| US20060148896A1 (en) | 2006-07-06 |
| DE60216090D1 (de) | 2006-12-28 |
| DK1399143T3 (da) | 2007-03-26 |
| WO2002096411A1 (en) | 2002-12-05 |
| KR20040003031A (ko) | 2004-01-07 |
| PL367628A1 (en) | 2005-03-07 |
| EP1399143A1 (en) | 2004-03-24 |
| HUP0400007A2 (hu) | 2004-04-28 |
| SK15862003A3 (sk) | 2004-06-08 |
| US20040171685A1 (en) | 2004-09-02 |
| DE60216090T2 (de) | 2007-05-31 |
| EP1399143B1 (en) | 2006-11-15 |
| MXPA03010920A (es) | 2004-02-27 |
| JP2004532867A (ja) | 2004-10-28 |
| PT1399143E (pt) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4166951B2 (ja) | 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ | |
| US20100048695A1 (en) | Anti-fatigue agent | |
| US20030119913A1 (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof | |
| EP0053175B1 (en) | Use of d-fenfluramine for the manufacture of a medicament for modifying feeding behavior | |
| BR112013028104A2 (pt) | composição e método para tratamento de diabetes | |
| WO2007142286A1 (ja) | 疲労軽減剤 | |
| CA3011633A1 (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| JP2003171271A (ja) | 耐糖能異常用薬剤 | |
| HUP0004336A2 (hu) | Készítmény alkoholistákban fellépő megvonási tünetek és alkohol iránti ellenállhatatlan szükségérzet elnyomására és az alkohol túlzott mértékű fogyasztásának megelőzésére egészséges alanyokban | |
| CN112716969A (zh) | 治疗阿尔茨海默症的组合物及其制备方法、应用 | |
| CZ20033222A3 (cs) | Použití alkanoyl L-karnitinu k přípravě léčiva k léčbě anhedonie | |
| JPH0699310B2 (ja) | アセトアルデヒド解毒剤 | |
| JP6044667B2 (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
| WO2004091598A1 (en) | Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol | |
| AU2002305132A1 (en) | Methods for increasing serotonin levels by administering (-)-hydroxycitric acid | |
| ZA200307594B (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating hydroxycitric acid and related compositions thereof | |
| HUP0202314A2 (en) | Use of acetyl l-carnitine and propionyl l-carnitine for producing a pharmaceutical composition for the prevention and treatment of kidney dysfunctions and diseases | |
| CN115381924B (zh) | 一种用于神经修复的组合物及其制备方法 | |
| RU2493841C1 (ru) | Синергетический препарат для лечения сердечно-сосудистых заболеваний, сахарного диабета и заболеваний гепато-билиарной системы | |
| Streeter et al. | Nutritional support in hepatic failure in dogs and cats | |
| Ban et al. | Psychopharmacology for everyday practice | |
| JP4715423B2 (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
| Aminoff | Basic & Clinical Pharmacology | |
| CN100413512C (zh) | 银杏提取物用于增加肌肉质量而减少脂肪质量的用途 | |
| Bucci et al. | The toxic effects of long-term, oral administration of L-tryptophan in rats with portacaval shunt |